Recent federal actions have accelerated partial rescheduling of marijuana while setting a defined timeline for broader changes. In December 2025, an executive order directed the Department of Justice to complete rulemaking for moving marijuana to Schedule III as quickly as federal procedures allow. This led to an April 2026 order that immediately placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective late April. The same action launched an expedited administrative hearing on June 29, 2026, to evaluate rescheduling all marijuana from Schedule I. These steps, building on the 2024 proposed rule and public comments, represent the primary drivers of current market positioning, with the June hearing serving as the next major procedural milestone that could influence full rescheduling outcomes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated$759,317 Vol.
June 30
2%
December 31
25%
$759,317 Vol.
June 30
2%
December 31
25%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...Recent federal actions have accelerated partial rescheduling of marijuana while setting a defined timeline for broader changes. In December 2025, an executive order directed the Department of Justice to complete rulemaking for moving marijuana to Schedule III as quickly as federal procedures allow. This led to an April 2026 order that immediately placed FDA-approved marijuana products and state-licensed medical marijuana into Schedule III, effective late April. The same action launched an expedited administrative hearing on June 29, 2026, to evaluate rescheduling all marijuana from Schedule I. These steps, building on the 2024 proposed rule and public comments, represent the primary drivers of current market positioning, with the June hearing serving as the next major procedural milestone that could influence full rescheduling outcomes.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated



Beware of external links.
Beware of external links.
Frequently Asked Questions